SCHEMBL2675689

SCHEMBL2675689

CC1CN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC(C)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 4/20 0.38
SIGMAR1 Q99720 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 2/20 0.38
SCARB1 Q8WTV0 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX15 P16050 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR2B P41595 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676871 0.88 REN (0.46) NPSR1L3MBTL1MAPK1TSHRMLNR
SCHEMBL2677142 0.88 REN (0.46) NPSR1L3MBTL1MAPK1TSHRMLNR
SCHEMBL2676873 0.88 REN (0.46) NPSR1L3MBTL1MAPK1TSHRMLNR
SCHEMBL2677389 0.86 SMN1; SMN2 (0.46) NPSR1L3MBTL1MAPK1MEN1KMT2A
SCHEMBL2677796 0.86 SMN1; SMN2 (0.46) NPSR1L3MBTL1MAPK1MEN1KMT2A
SCHEMBL2674644 0.85 MAPK1 (0.42) NPSR1L3MBTL1MAPK1CYP3A4MEN1
SCHEMBL2676260 0.83 ACHE (0.45) NPSR1L3MBTL1MAPK1CYP3A4MEN1
SCHEMBL1716812 0.83 TACR3 (0.43) NPSR1MAPK1CYP3A4MEN1KMT2A
SCHEMBL2676758 0.81 HRH3 (0.46) NPSR1CYP3A4MEN1KMT2AALDH1A1
SCHEMBL2676392 0.81 MAPK1 (0.45) NPSR1L3MBTL1MAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 NPSR1 182/4885L3MBTL1 4591/4885MAPK1 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.